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without prevention therapy revealed a significant (p<0,05) reduction of BMD (LS -1,9%, 
FN -4,1%) and z-score (LS -1,5%, FN -3,6%) within 12 months. The fracture incidence 
was 6%. LS-BMD loss correlated negatively (r=-0,7; p<0,01) with the increase in iPTH 
and iPTH correlated positively with craatinine (r=0,51; p<0,05). Pts. with calcium supple- 
mentation demonstrated also a 6% fracture incidence and a decrease in BMD (LS -0,9%, 
FN -1,2%) as well as z-score (LS -0,9%, FN -0,9%) which was not statistically significant. 
BMD and z-score were not significant different between both groups. Conclusions: Pts. 
with CHF demonstrate a progressive decrease in BMD in comparison to age-matched 
healthy individuals. Increased bone resorption due to a secondary hyperparathyroidism 
is a frequent reason for this BMD loss. Calcium supplementation alone can not suffi- 
ciently prevent the decrease in BMD. Depending of the individual BMD-status an addi- 
tional therapy with vitamin D and / or bisphosphonates should be recommended for pts. 
with CHF. 
1134-147 Ef fects  of  Neslr l t lde (B-Type Natr iuret ic  Peptide) on 
Pulmonary Artery Pressures In Pat ients  With Acute 
Decompenseted Congestive Heart Failure 
James B. Youno. The Cleveland Clinic Foundation, Section of Heart Failure and Cardiac 
Transplant Medicine, Cleveland, Ohio. 
Baekoround: The rapid end significant reductions in pulmonary capillary wedge pres- 
sure and dyspnea with the use of nesiritide in patients with acutely decompensated con- 
gestive heart failure (CHF) have been previously described. Because patients with CHF 
frequently have concomitant pulmonary hypertension, the effects of nesiritide and intra- 
venous nitroglycerin (IV NTG) on pulmonary pressures were explored in a large, random- 
ized, controlled trial (Vasodilation in the Management of Acute CHF - VMAC) that 
enrolled patients with acutely decompensatad CHF and NYHA class IV symptoms on 
presentation. 
Mothods: In VMAC, the randomization was stratified based on investigator decision to 
use a pulmonary artery catheter for patient management or not. Hospitalized patients 
with acutely decompensetad CHF were randomized to nesidtide (n=124), placebo 
(n=62), or IV NTG (n=60). 
Ruults:  Mean pulmonary artery systolic (PAS) and diastolic (PAD) pressures were ele- 
vated at baseline (59.2 + 12.9 and 28.4 + 7.09 mmHg, respectively), but were compara- 
ble in the 3 treatment arms. Nssiritide was superior to placebo at all time points and to IV 
NTG at most time points at reducing PAS and PAD (see figure). 
Conclusion: Nesiritide, but not IV NTG, effectively and rapidly reduces pulmonary pres- 
sures compared to placebo. In patients with acute CHF end elevated pulmonary pres- 
sures, nesiritide is the preferred firstline IV agent. 
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1134-148 Does Digitalis Influence the Response to Beta-Blockade 
in Patients With Severe Chronic Heart Failure? Results 
of the COPERNICUS Study 
Alan B. Miller. Chdstopher O'Connor, Andrew J. Coats, Henry Krum, Michel Tendera, 
Paul Mohasci, Jean L. Rouleau, Michael B. Fowler, Hugo A. Katus, Ellen B. Roecker, 
Milton Packer, for the COPERNICUS Study Group, University of Florida, Jacksonville, 
Florida. 
Background. Most trials demonstrating the efficacy of J]-blockers (~B) in chronic heart 
failure (HF) enrolled patients receiving digitalis (DIG). Thus, little is known about the effi- 
cacy and safety of !3B in patients who are not digitalized. Like I~B, DIG may attenuate the 
effects of the sympathetic nervous system, but unlike ~B, DIG exerts positive inotropic 
effects that may be valuable in ~-btocked patients. 
Methods. To evaluate this possibility, we assessed the effects of carvedilol (CRV) vs pla- 
cebo (PBO) in patients with severe HF enrolled in the COPERNICUS study. Of the 2289 
patients in the trial, 1513 were receiving DIG (PBO 733, CRV 780) and 776 were not 
receiving DIG (PBO 400, CRV 376) at the time of randomization. Results: Shown below 
are 1-year Kaplan-Meier rates and Cox model (CRV:PBO) hazard ratios. 
All-Cause Mortality Death or HF Hospitalization 
Digitalis No Digitalis Digitalis No Digitalis 
Placebo 19.6% 16.1% 39.8% 33.8% 
Carvedilol 12.8% 8.0% 26.7% 23.1% 
Hazard ratio 0.71 0.48 0.71 0.64 
(95% CI) (0.55-0.91) (0.30-0.77) (0.59-0.85) (0.47-0.87) 
The effects of CRV on all-cause mortality and on death or HF hospitalization in patients 
not receiving DIG were at least as large as in those receiving DIG (interaction P values 
for DIG vs non-DIG were not significant). The rate of permanent withdrawal was lower 
with CRV than PBO and was similar in DIG and no-DIG patients (interaction P=0.25). 
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DIG did not increase the dsk of bradycardia attributable to CRV. 
Conclusions. These results indicate that DIG is not required for the efficacy or safety of 
CRV in severe chronic HF. Since CRV (but not DIG) reduces mortality, these data sup- 
port the use of CRV before DIG in HI=. 
1134-149 Endogenous  Ouaba in -L lke  Factor Predicts Progression 
Toward Heart Fai lure in Pat ients  With Id lopeth l¢ Di lated 
Card iomyopethy  
Maria V. Pitzalis, Paolo Manunta, Messimo lacoviello, Elisabetta Messaggio, Cinzia 
Fodeo, Roberta Romito, Viviana De Luce, Giuseppe Bianchi, Paolo Rizzon, Elisabetta 
De Tommasi, Institute of Cardiology, Bari, Italy, Division of Nephrology, Dialysis and 
Hypertension, Milan, Italy. 
Background. Plasma levels of endogenous ouabain factor (OLF) have shown to be 
increased in patients with left ventdcular dysfunction. Since it increases pedpheral resis- 
tance, sympathetic activity and cytokine excretion, OLF could favour the progression 
towards heart failure. The aim of this study was to assess the prognostic role of OLF in a 
group of patients with idiopathic dilated cardiomyopathy (WHO criteda). 
Methods. Ejection fraction (EF; mean 37%±11%), and plasma OLF levels (rddioimmu- 
nasaay method, mean 263.4±135.1) were assessed in 114 consecutive patients (age 
51 ±15 years; 89 male; 33 in NYHA class I, 62 in II, 19 in III), while receiving optimal ther- 
apy. Heart failure progression was defined by the appearance of a worsening in clinical 
conditions leading to one of the following: sustained increase in conventional therapies, 
hospitalization, cardiac transplant, death. 
Results. After 13±5 months of follow-up, 9 patients had a sustained increase of conven- 
tional therapy, 14 a hospitalization for heart failure, 2 cardiac transplantat and 1 died after 
worsening of heart failure. The prognostic significance of age, EF, NYHA class and OLF, 
at univariate and multivariate Cox regression analysis is shown in the table. 
Conclusions. High OLF plasma levels are independent predictors of heart failure pro- 
9ression in idiopathic dilated cardiomyopathy patients. 
Vadable Univariata analysis Multivadate analysis 
RR (95% CI) p RR (95% CI) p 
Age 1.04 (1.01-1.08) 0.01 1.00 (0.96-1.04) NS 
NYHA class 6.21 (3.10-12.44) <0.0001 3.02 (1.24-7.34) 0.02 
LVEF 0.9 (0.86-0.94) <0.0001 0.93 (0.88-0.98) 0.01 
OLF 1.002 1.001-1.003) <0.0001 1.0015 (1.0003-1.003) 0.01 
1134-150 The Use of Beta-Blockers in a University Hospital Heart 
Function Clinic: Insights Into Dosing and Tolerance 
Puneeta Tandon, Finlay A. McAlister, Ross T. Tsuyuki, Marilou Hervas-Malo, Shane 
Kimber, Paul W. Armstrong, University of Alberta, Edmonton, Alberta, Canada. 
BACKGROUND: Although multiple trials have conclusively proven that beta-blockers are 
beneficial in CHF, they appear to be under-prescribed in actual practice. The reasons for 
this underuse are uncertain. 
METHODS: A retrospective analysis of the Heart Function Clinic database at the Univer- 
sit,/of Alberta Hospital, Edmonton, Canada for the years 1989 to 2000 (a cohort of 932 
patients with a diagnosis of CHF confirmed by a cardiologist, objective measurements of 
LVEF at baseline, and prospective collection of clinical, laboratory, and pharmacy data at 
all subsequent clinic visits). 
RESULTS: Mean age at baseline was 73 years, 55% were female, 76% had systolic dys- 
function, 69% had an isohemio etiology, mean LVEF was 33%, and 51% had NYHA class 
III or IV symptoms. Over this pedod of time, beta-blockers were prescdbed for 42% of 
patients: patients were less likely to be prescribed a beta-blocker if they were over the 
age of 75 years (p=O.004), had NYHA class III or IV symptoms (p<0.0001), had a diagno- 
sis of COPD (p=0.0004), or had a resting HR< 60 at baseline (p=0.02). Baseline LVEF 
and BP were not different between those presodbed and not prescdbed beta-blockers. In 
those prescribed beta-blockers, the mean maximum daily doses achieved during fol- 
Iowup were less than those achieved in clinical trials (25.9 mg for cervedilol, 52.6 mg for 
atanolol, 77.3 mg for metoprolol, and 143.4 mg for acebutolol). Mean time to achieve 
maximum dose was 12 months and 29% of patients had their dosage reduced after 
achieving their maximum dose: there were no significant differences in mean BP, HR, or 
recorded symptoms before beta blockers were prescribed and in followup visits after 
maximum doses were achieved. 
CONCLUSIONS: Beta-blockers were under-used and under-dosed in this patient popu- 
lation relative to the tdal evidence; while the under-use was partially accounted for by 
patient factors, the under-dosing did not appear to be related to BP, HR, or NYHA class 
(suggesting that unmeasured factors, such as patient complaints of fatigue, may have 
limited the up-titration of beta-blockers in these patients). Prospective data collection is 
needed to examine the reasons for failure to achieve target doses of beta-blockers in 
CHI£ 
1134-151 Inc idence of  Ang ioedema in SOLVD 
John B. Kostis, Alan C. Wilson, UMDNJ-Robert Wood Johnson Medical School, New 
Brunswick, New Jersey. 
Background: Angioedema (AE) is a well recognized adverse effect of treatment with 
ACE inhibitors. However, there is wide variation in the reported rate of AE occurrence. 
Methods: We used data from the Studies of Left Ventricular Dysfunction (SOLVD), a 
clinical trial compadng enalapril to placebo in patients with left ventdcular dysfunction. 
Participants (pts) were given single blind enalapdl 2.5 mg bid for 1 week followed by pla- 
cebo for 2 weeks dudng a run-in phase, then randomized to double blind placebo or enal- 
april titrated to 10 mg bid and followed for an mean of 40 months. Two different methods 
of ascertaining the occurrence of AE were used sequentially in SOLVD: in the first 3567 
